メインコンテンツにスキップ
検索

早期臨床

登録

最新のリソース

注目コンテンツ

Upcoming early clinical webinars

Latest early clinical blogs

医薬品開発におけるPK/PDモデリングのための機械学習
Machine Learning for PK/PD Modeling in Drug DevelopmentBlog

医薬品開発におけるPK/PDモデリングのための機械学習

米国FDAのモデルに基づく医薬品開発と対になったパイロットプログラムが治験依頼者を助ける方法
How the US FDA MIDD paired pilot program helps sponsorsBlog

米国FDAのモデルに基づく医薬品開発と対になったパイロットプログラムが治験依頼者を助ける方法

指標となる臨床的薬剤相互作用研究における代謝物の測定
Measuring metabolites in index clinical DDI studiesBlog

指標となる臨床的薬剤相互作用研究における代謝物の測定

Why FDA’s omaveloxolone approval for Friedreich’s ataxia matters
Why FDA’s omaveloxolone approval for Friedreich’s ataxia mattersBlog

Why FDA’s omaveloxolone approval for Friedreich’s ataxia matters

Key development considerations for cell therapies
Key development considerations for cell therapiesBlog

Key development considerations for cell therapies

医薬品開発のリスク軽減：早期開発における重要な化学、製造、および管理（CMC）および生理学的薬物動態（PBPK）アプローチ
De-risking Drug Development: Key Chemistry, Manufacturing, and Controls (CMC) and Physiologically Based Pharmacokinetic (PBPK) Approaches in Early Development Blog

医薬品開発のリスク軽減：早期開発における重要な化学、製造、および管理（CMC）および生理学的薬物動態（PBPK）アプローチ

以下のイベントで弊社のエキスパートをご紹介

展示会・学会

ISSX 2025 International Meeting

September 12 - 14, 2025 – Chicago, Illinois
対面セミナー・イベント

Certainty Korea 2025​

2025年9月18日 – Conrad Seoul
対面セミナー・イベント

Certainty China 2025​

2025年9月23日 – Crowne Plaza Shanghai Jinxiu

All early clinical resources

Quantitative Systems Pharmacology-Based Digital Twins Approach for Clinical Development in Rare Diseases

Modeling and Simulation - QSP, Webinar

Pirana Tips and Tricks – Report Object Generation in Pirana

サターラの製品、ウェビナー

The Reference-scaled Average Bioequivalence (RSABE) Approach

Certara Products, Certara Products - Phoenix, Modeling and Simulation - PK/PD, Blog

5 Clinical Development Challenges Model-Based Meta-Analysis (MBMA) Helps Address

Certara Products, Certara Services, Clinical Trials, Drug Development, Model Informed Drug Development, Model-Based Meta-Analysis (MBMA), Modeling and Simulation, Modeling and Simulation - PK/PD, Blog

How Model-informed drug development rescue projects from a risky situation​

Certara Services, Clinical Pharmacology, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Case Study

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

Certara Services, Clinical Trials, Drug Development, Drug Safety, Model Informed Drug Development, Modeling and Simulation, Therapeutic Specialties, Publication

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Certara Services, Clinical Pharmacology, Drug Development, Drug Safety, Infectious Disease, Model Informed Drug Development, Model-Based Meta-Analysis (MBMA), Modeling and Simulation, Modeling and Simulation - PK/PD, Therapeutic Specialties, Webinar

Faster Mapping from Source Data to Target SDTM

Certara Products - Pinnacle 21, Webinar

Redefining Regulatory Strategy with MIDD: Insights from the Draft ICH M15 Guidance

Certara Products - Simcyp, Modeling and Simulation, Modeling and Simulation - PBPK, Pharmacometrics, Blog

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

Certara Products - Phoenix, Certara Products - Pinnacle 21, Certara Services, Clinical Pharmacology, Clinical Trials, Data Standards, Drug Development, Model Informed Drug Development, Modeling and Simulation - PK/PD, Webinar - Resources LP - Upcoming, Webinar

EACPT 2025 CONGRESS

Conference - Early Clinical LP, Conference - Preclinical LP, Conference LP - Latest, Drug-Drug Interactions (DDI), Conference

What are the most common in vitro drug-drug interaction study gaps?

Drug Safety, Drug-Drug Interactions (DDI), Blog
ニュースレターを購読

今すぐ登録：医薬品開発の革新は、サターラの情熱そのものです。最新情報を入手し、ともに科学の限界を切り拓いていきましょう。


Powered by Translations.com GlobalLink Web Software